| Pharmatek’s Drug Development Risk Assessment Scorecard was designed to improve efficiency and reduce potential risk in drug development programs. The Scorecard is a quantitative approach to assessing risk in oral drug development programs with respect to Chemistry, Manufacturing, and Controls (CMC) activities. It is a tool created to help project managers identify drug program risks and provides them with a dashboard view of critical areas in the drug development process. Pharmatek’s Scorecard is based on evaluations of hundreds of different drug candidates by Pharmatek scientists over the last 12 years.
*For further information on Pharmatek’s Drug Development Risk Assessment Scorecard, or for help scoring compounds in development, download our white paper: Assessing Risk in Oral Drug Development Programs.
Take our Risk Assessment Test and measure the potential risks in your drug development program now: Drug Development Risk Assessment Scorecard.
|
|
Each drug candidate is unique. No one program can be scripted to cover every unique chemical entity. At Pharmatek, each program is developed around critical endpoints: an easily manufacturable drug product, a final dosage form that ensures good patient compliance and the company's corporate objectives. |
